Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Tempo Scan Pacific Tbk (TSPC.JK)
Jakarta, ID
PT Tempo Scan Pacific Tbk, an Indonesian company headquartered in Jakarta with an international presence, operates primarily across three core business segments: pharmaceuticals, consumer products and cosmetics, and distribution services. Its activities encompass the trading of pharmaceutical and medical devices, alongside the manufacturing of diverse goods such as soaps, herbal products, powdered milk, food and beverages, and plastic packaging. The company also produces and markets a variety of consumer goods, cosmetic lines, and household items. Products are sold under an extensive portfolio of brands, including Bodrex, Oskadon, Neo rheumacyl, Bodrexin, Contrexyn, Contrex, Oskadryl, Neodulax, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Vitamin IPI, Neo rheumacyl Herbal, Wybert Herbal, Bodrexin Herbal, Herbalax, Marina, Natural Honey, Claudia, MY BABY, MY BABY Kids, Pure Baby, S.O.S, Total Care, and ULTIMA II. Beyond these, PT Tempo Scan Pacific Tbk offers a range of supplementary services, including property construction and leasing, warehousing and freight forwarding, advertising and promotion, research and development, and information technology and communication network systems. It also manages procurement, distribution, and marketing functions. Established in 1970, the company was formerly known as PT Scanchemie and functions as a subsidiary of PT Bogamulia Nagadi.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.84% | -0.84% | -2.87% | -12.87% | -15.05% | -16.84% | -9.54% | +62.89% | +55.92% | +24.41% | +233.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.6% Q1'26: +4.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-2.8% Q1'26: -14.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.5% Q1'26: +4.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+11.4% Q1'26: +12.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+21.7% ★ Q1'26: +23.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.55× ★ Q1'26: 0.59× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
10.09T
est: 11.11B (+90,674.4%)
|
10.99T
est: 12.34B (+88,999.8%)
|
| EBITDA |
955.56B
est: 1.60B (+59,771.5%)
|
1.01T
est: 1.77B (+57,144.9%)
|
| EBIT |
702.58B
est: 1.31B (+53,581.9%)
|
797.08B
est: 1.45B (+54,754.2%)
|
| Net Income |
512.03B
|
554.26B
|
| SGA |
2.10T
est: 1.95B (+107,802.4%)
|
2.30T
est: 2.16B (+106,202.4%)
|
| EPS |
113.78
|
123.17
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-26 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-25 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| F. Cisca Dwijani | Managing Director of Prescription Medicine Group | — | — |
| Galang Putra Ariyanto | Head of Internal Audit of Distribution Division | — | male |
| Kartika Chandra Sutantio | Corporate Finance & Treasury Director | — | — |
| Linda Lukitasari | Research & Development Director and Director | — | female |
| Made Dharma Wijaya | President Director and MD of Sales & Operation - Distribution Division | — | male |
| Nina Muthmainnah | Managing Director of International Business and License Cosmetics | — | female |
| Shania | Group General Counsel Director, Corporate Secretary & Director | — | female |
| Swasta Kusnadi | Head of Internal Audit | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TSPC.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
